Preclinical pharmacology, antitumor activity and development of pharmacodynamic markers for the novel, potent AKT inhibitor CCT128930

AKT is frequently deregulated in cancer, making it an attractive anticancer drug target. CCT128930 is a novel ATP-competitive AKT inhibitor discovered using fragment and structure-based approaches. It is a potent, advanced lead pyrrolopyrimidine compound exhibiting selectivity for AKT over PKA, achi...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Mol Cancer Ther
Prif Awduron: Yap, Timothy A., Walton, Mike I., Hunter, Lisa-Jane K., Valenti, Melanie, de Haven Brandon, Alexis, Eve, Paul D., Ruddle, Ruth, Heaton, Simon P., Henley, Alan, Pickard, Lisa, Vijayaraghavan, Gowri, Caldwell, John J., Thompson, Neil T., Aherne, Wynne, Raynaud, Florence I., Eccles, Suzanne A., Workman, Paul, Collins, Ian, Garrett, Michelle D.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: 2010
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC4944842/
https://ncbi.nlm.nih.gov/pubmed/21191045
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-10-0760
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg